Autoinflammatory & rare systemic diseases
Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AutoInflammatory Disease Alliance (AIDA) network registry
Main finding · Treatment discontinuation due to long-term remission (logistic regression)Result — go to the resultOR for treatment discontinuation due to long-term remission 4.83 95% CI 1.08–23.19Authors' conclusion
Early canakinumab initiation is associated with treatment discontinuation due to long-term remission and appears linked to a greater frequency of a monocyclic disease course.
Study context
- Population
- Patients with Still's disease (SD) treated with canakinumab, international AIDA Network registry
- Participants
- 190 patients
- Exposure
- Canakinumab started ≤3 months vs >3 months from disease onset
- ≤3 monthsn = 35
- >3 monthsn = 155reference
- Outcome
- Treatment discontinuation due to long-term remission, GC sparing effect and frequency of monocyclic disease course
Methodological detailsinternational registry, logistic regression analysis
- International registry
- Logistic regression analysis
Main finding
As reported in the abstract
Treatment discontinuation due to long-term remission (logistic regression)
OR for treatment discontinuation due to long-term remission
4.83
95% CI 1.08–23.19
P = 0.04
≤3 monthsvs >3 months
OR for treatment discontinuation due to long-term remission 4.83 (95% CI 1.08–23.19); P = 0.04
Observational data: associations, not effects.
Further findings
Reduction in GC use · month 3
P = 0.0001
Reduction in GC use · month 6
P = 0.004
Monocyclic disease course
P < 0.0001
| Outcome | RRR (95% CI) | P value |
|---|---|---|
| Monocyclic vs chronic-articular and polycyclic course, with start ≤3 monthsMonocyclic vs chronic-articular course | 4.43 (1.12–17.60) | P = 0.034 |
| Monocyclic vs chronic-articular and polycyclic course, with start ≤3 monthsMonocyclic vs polycyclic course | 8.97 (1.29–62.3) | P = 0.03 |
Original publication
Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA network registry. Semin Arthritis Rheum. Published 20 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →